Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accounts Payables: 2013-2024

Historic Accounts Payables for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $65.5 million.

  • Fortress Biotech's Accounts Payables fell 29.97% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year decrease of 29.97%. This contributed to the annual value of $65.5 million for FY2024, which is 10.96% down from last year.
  • Latest data reveals that Fortress Biotech reported Accounts Payables of $65.5 million as of FY2024, which was down 10.96% from $73.6 million recorded in FY2023.
  • Fortress Biotech's Accounts Payables' 5-year high stood at $97.4 million during FY2022, with a 5-year trough of $45.4 million in FY2020.
  • For the 3-year period, Fortress Biotech's Accounts Payables averaged around $78.8 million, with its median value being $73.6 million (2023).
  • Per our database at Business Quant, Fortress Biotech's Accounts Payables spiked by 99.74% in 2021 and then dropped by 24.51% in 2023.
  • Fortress Biotech's Accounts Payables (Yearly) stood at $45.4 million in 2020, then spiked by 99.74% to $90.7 million in 2021, then rose by 7.49% to $97.4 million in 2022, then fell by 24.51% to $73.6 million in 2023, then declined by 10.96% to $65.5 million in 2024.